Filed with ASX · · 2 pages · English
Neurizon Therapeutics Limited has announced the extension of its non-dilutive R&D financing facility with the Dare Capital Loan Fund to cover its R&D Tax Incentive claim for the upcoming financial year. This strategic funding allows Neurizon to better manage its cash flow related to R&D investments, particularly for the HEALEY ALS Platform Trial. The CEO emphasized the importance of this facility in providing non-dilutive capital as the company prepares for significant trial results in the near future.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Neurizon Extends Non-Dilutive R&D Facility to FY2027 and Completes Second Drawdown Highlights: • Research and Development (R&D) financing facility with the Dare Capital Loan Fund extended to cover Neurizon’s FY2027 R&D Rebate •...
Neurizon Therapeutics Limited on 6ix
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics